Biomarker Core

生物标志物核心

• 批准号: 10263689
• 负责人: ALLEN W SONG
• 金额: $ 57.91万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10263689
• 关键词: Affect; Algorithms; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Amyloid; Area; Biological Markers; Blood; Brain; Brain imaging; Caliber; Cells; Clinical; Collaborations; Communities; Cortical Column; Data; Data Analyses; Databases; Dementia; Detection; Development; Disease; Disease Progression; Early Diagnosis; Enrollment; Environmental Risk Factor; Faculty; Family; Funding; Genetic Risk; Genomics; Goals; Human; Image; Image Analysis; Imaging Device; Individual; Investigation; Knowledge; Lead; Magnetic Resonance Imaging; Measures; Methodology; Modality; Monitor; Nerve Degeneration; Neurodegenerative Disorders; Organ; Participant; Patients; Positron-Emission Tomography; Prevention; Proteins; Proteomics; Provider; Research; Research Personnel; Research Project Grants; Resolution; Resources; Sensory; Signal Transduction; Standardization; Structure; Symptoms; Synapses; Time; Tracer; Training; Work; adjudicate; age related; biomarker development; cohort; data acquisition; data management; density; disease diagnosis; early detection biomarkers; education research; experience; high risk population; human old age (65+); human subject; imaging biomarker; improved; innovation; magnetic resonance imaging biomarker; metabolomics; next generation; novel; novel marker; outreach; pre-clinical; recruit; resilience; retinal imaging; standardize measure; statistics; tau Proteins; wearable device

ABSTRACT – BIOMARKER CORE The objective of the Biomarker Core is to acquire and analyze biofluid and imaging biomarkers, characterize their relevance to Alzheimer’s disease (AD), and determine the underlying age-related factors that drive the development, progression, or experience of the disease. To achieve these goals, we bring together experts across diverse backgrounds in genomics, proteomics, metabolomics, and imaging to provide institutional resources to serve ADRC investigators, help initiate new collaborations, and train the next generation of AD and Alzheimer’s disease-related dementia (AD+ADRD) biomarkers researchers. Specifically, we propose four aims: 1) Acquire conventional and novel biomarkers in biofluid (CSF, blood), brain images (PET, MRI), and sensory organ data (retinal imaging) in adjudicated participant groups. Working closely with the Clinical Core, we will acquire CSF, blood, PET and MRI biomarkers in our clinical cohort to submit to the National Alzheimer’s Coordinating Center (NACC). At the same time, we will collaborate closely with independently funded research projects to acquire novel and early biomarkers in high-risk populations during the prodromal or early symptomatic stages of AD pathology. 2) Analyze biomarkers to obtain standardized measures and support relevant funded research projects within the ADRC community. We will perform standardized analyses in biofluid and imaging data to extract conventional biomarkers, and collaborate with existing funded projects to develop specialized analytics to identify novel biomarkers that can lead to earlier detection and prevention. 3) Provide resources to ADRC researchers integrating standardized multi-dimensional biomarkers data across all participants to characterize the underlying age-related drivers for AD. Working closely with the Data Management and Statistics Core, we will create and curate a multi-dimensional database, integrating all acquired biomarkers and clinical measures. This database will be used to assist and train the next generation of AD researchers in their investigations of underlying age-related drivers of AD, through collaborations with the Research Education Component. 4) Disseminate our expertise and knowledge to support the AD community at large. Working with the Outreach, Recruitment, and Engagement Core, we will disseminate our expertise and knowledge on established and emerging biomarkers to the local AD stakeholder community, other ADRC centers, and AD+ADRD researchers and providers across the nation. Through these four aims, we hope to help achieve our overall objective to catalyze and support high- caliber research and innovations to reduce the burden of AD and its impact on patients and families.

抽象生物标志岩心 Biomarker Core的目标是获取和分析生物流体和成像生物标记物，表征 与阿尔茨海默病(AD)的相关性，并确定潜在的年龄相关因素，推动 疾病的发展、进展或经历。为了实现这些目标，我们召集了专家 跨越基因组学、蛋白质组学、代谢组学和成像领域的不同背景，为机构提供 为ADRC调查人员提供服务的资源，帮助启动新的协作，并培训下一代AD 和阿尔茨海默病相关痴呆(AD+ADRD)生物标记物的研究人员。具体来说，我们建议 四个目标：1)获得生物体液(脑脊液、血液)、脑图像(PET、MRI)的常规和新型生物标记物， 以及被判定的参与者组的感官数据(视网膜成像)。与临床医生密切合作 核心，我们将获得我们临床队列中的脑脊液、血液、PET和MRI生物标记物，提交给国家 阿尔茨海默病协调中心(NACC)。同时，我们将与独立的公司密切合作 资助研究项目，在先兆期间在高危人群中获得新的和早期的生物标记物 或AD病理的早期症状阶段。2)分析生物标志物，以获得标准化的措施和 支持ADRC社区内相关资助的研究项目。我们将执行标准化的 分析生物流体和成像数据，以提取常规生物标志物，并与现有的 资助项目，以开发专门的分析，以确定可能导致更早检测的新生物标志物 和预防。3)为ADRC研究人员提供资源，整合标准化的多维 所有参与者的生物标记物数据，以表征AD的潜在年龄相关驱动因素。劳作 与数据管理和统计核心紧密合作，我们将创建和策划一个多维 数据库，整合所有已获得的生物标记物和临床措施。该数据库将用于协助和 培训下一代AD研究人员对AD潜在的年龄相关驱动因素进行调查， 通过与研究教育部门的合作。4)传播我们的专业知识和 支持整个AD社区的知识。与外联、招聘和接洽一起工作 核心，我们会将我们在现有和新兴生物标志物方面的专业知识传播给当地的 广告利益相关者社区、其他ADRC中心以及AD+ADRD研究人员和提供商 国家。通过这四个目标，我们希望有助于实现我们的总体目标，即催化和支持高质量的 为减轻AD的负担及其对患者和家庭的影响而进行的研究和创新。